Core Viewpoint - Lijun Pharmaceutical (01513) announced a strategic transaction involving the capital increase and equity transfer agreement with its controlling shareholder, Health元, and a subsidiary, 毛孩子, aimed at optimizing asset structure and focusing on core pharmaceutical business [1] Group 1: Transaction Details - The agreement stipulates that 心有毛孩 will increase its capital contribution to 毛孩子 by RMB 15 million, while Health元 will transfer its 49% equity stake in 毛孩子 to 心有毛孩 [1] - Following the transaction, 心有毛孩 will hold 52.56% of 毛孩子, while Lijun Pharmaceutical's stake will be diluted from 51.00% to 47.44%, and Health元 will no longer hold any equity in 毛孩子 [1] Group 2: Strategic Focus - The transaction aligns with the company's strategy to concentrate on pharmaceutical research, production, and sales, while recognizing the growth potential in the pet medicine industry [1] - Post-transaction, the company plans to allocate more resources and focus on technological innovation and market expansion within the pharmaceutical sector, thereby enhancing profitability and aligning with long-term development strategies [1]